Clinical Trial NCT04901936

Trial

Apellis – APL2-PNH-209

Clinical trial ID

NCT04901936

Drug name

APL-2 Pegcetacoplan

Company:

Apellis

Drug trade name

Empaveli® Aspaveli®

Phase of study

2

Current status

Recruiting

Start

02/2021

Substance

Cyclopeptide

Research question

Pediatric

Delivery method of drug

s.c.

Frequency

2 x weekly

Clinical trial locations

Czechia France Malaysia Netherlands Serbia Spain Thainland UK USA